Black Diamond Therapeutics, Inc.
BDTX • NASDAQ
Black Diamond Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Mark A. Velleca, with a market cap of $116.3M.
CEOMark A. Velleca
Next Earnings
Upcoming earnings announcement for Black Diamond Therapeutics, Inc.
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.20
Revenue Estimate
$30.0M
Earnings History
Past 12 earnings reports for Black Diamond Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Q4 2025 | -$0.27Est: -$0.17 | -58.8% | - | — |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.15Est: -$0.22 | +31.8% | - | — | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.19Est: -$0.24 | +20.8% | - | — | 10-Q |
| May 12, 2025 | Q1 2025 | $0.98Est: $0.10 | +880.0% | $70.0MEst: $23.3M | +200.0% | 10-Q |
| Mar 6, 2025 | Q4 2024 | -$0.28Est: -$0.31 | +9.7% | - | — | 10-K |
| Nov 5, 2024 | Q3 2024 | -$0.28Est: -$0.35 | +20.0% | - | — | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.36Est: -$0.39 | +7.7% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.35Est: -$0.44 | +20.5% | - | — | 10-Q |
| Mar 12, 2024 | Q4 2023 | -$0.34Est: -$0.47 | +27.7% | - | — | 10-K |
| Nov 6, 2023 | Q3 2023 | -$0.45Est: -$0.46 | +2.2% | - | — | — |
| Aug 11, 2023 | Q2 2023 | -$0.52Est: -$0.54 | +3.7% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.57Est: -$0.61 | +6.6% | - | — | — |